Vaccine side effects, ciclesonide for outpatients, COVID-19 in newborns, portable air purifiers to reduce airborne transmission

Peer reviewed journals featured:

- Systematic reviews on:
  - Adverse events in active and placebo groups in COVID-19 vaccine randomised trials [here](#)
  - Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists [here](#)
  - The efficacy and safety of Sarilumab in COVID-19 [here](#)
- Randomised controlled trials of:
  - Inhaled and intranasal ciclesonide for COVID-19 treatment in adult outpatients [here](#)
  - Seven day treatment with angiotensin II type 2 receptor agonist in hospitalised COVID-19 patients [here](#)
  - Nafamostat in hospitalised patients with moderate to severe COVID-19 pneumonia [here](#)
- A narrative review on inequalities in COVID-19 vaccine initiation by age and population in Israel [here](#)
- Observational studies on:
  - Illness severity indicators in newborns by COVID-19 status in the US [here](#)
  - Viral loads of Delta variant breakthrough infections after Comirnaty (Pfizer) vaccination and booster [here](#)
  - The effectiveness of Johnson & Johnson vaccine in preventing COVID-19 [here](#) and associated commentary [here](#)
  - Side effects and immunogenicity after Sputnik V vaccination [here](#)
  - Indirect impact of COVID-19 on hospital care pathways in Italy [here](#)
  - Optimising and evaluating PCR-based pooled screening in COVID-19 [here](#)
- An editorial on COVID-19 prevention in populations experiencing multiple social exclusions [here](#)

Pre-peer review articles featured:

- Using portable air purifiers to reduce airborne transmission of infectious respiratory viruses [here](#)
Guidance and reports


News and blogs

- Why scientists worldwide are watching UK COVID-19 infections [here](#)

Click here to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on COVID-19 transmission, SARS-CoV-2 vaccines, and variants of concern, post-acute sequelae of COVID-19 (PASC), surgery and COVID-19, rapid testing and risk mitigation strategies.